News | December 10, 2009

Anti-Coagulant Gains European Approval for STEMI PCI Patients


December 10, 2009 – European approval was recently granted for the use of Angiox (bivalirudin) as an anti-coagulant in patients with ST-segment elevated myocardial infarction (STEMI) who undergoing emergency primary percutaneous coronary intervention (PCI).

The commission decision extends the current EU license for Angiox and is applicable to all member states of the European Union. The manufacturer, The Medicines Company, said it will launch Angiox for the new indication in January 2010.

The approval was based on the landmark HORIZONS-AMI study, which was the first drug trial to demonstrate a reduction in deaths from heart attacks in patients undergoing emergency PCI. The trial showed that patients treated with Angiox compared with today’s leading treatment - heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) – were more likely to survive and had less frequent severe bleeds.

“The HORIZONS trial is the most recent demonstration of the efficacy of bivalirudin and shows a remarkable reduction of mortality in patients with STEMI undergoing primary PCI,” said professor Christian Hamm, director of the department of cardiology and medical director, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany. “The robustness of these findings from this trial is impressive and reflects a landmark in the treatment of these high risk patients in Europe.”

The HORIZONS-AMI trial compared Angiox to heparin plus a GPI in 3,602 patients (57 percent of whom were recruited in Europe) presenting with the most severe form of heart attack, known as STEMI, undergoing a PCI.

Results at 30 days showed that Angiox significantly improved overall mortality including a reduction in the incidence of heart-related deaths by 38 percent, reduced the incidence of major bleeding by 42 percent and significantly reduced the incidence of net adverse clinical events by 26 percent. The drug also demonstrated comparable rates of major adverse cardiac events (5.4 vs. 5.5 percent).

Angiox is a direct thrombin inhibitor with a naturally reversible mechanism of action and 25 minute half-life. In clinical trials.

For more information: www.themedicinescompany.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now